Ipsen delivers strong sales growth of 20.2% for the third quarter of 2018 and confirms full year guidance

- 25 October 2018 - 1 mins read

Paris (France), 25 October 2018 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2018.

Financial highlights

Q3 2018 Group sales growth of 20.2%1 driven by Specialty Care sales growth of 24.2%1 reflecting strong momentum for Somatuline® and Dysport®, continued sequential sales growth for Cabometyx® and Onivyde®, and growth of Consumer Healthcare sales of 5.0%2
YTD Group sales growth of 21.1%1 fueled by strong Specialty Care sales growth of 25.8%1 and Consumer Healthcare sales growth of 2.9%2
Full Year 2018 guidance confirmed with Group sales growth of greater than 19.0%1 and core operating margin of around 29.0% of sales

Pipeline highlights

Positive CHMP (Committee for Medicinal Products for Human Use) opinion for Cabometyx® for the treatment of second-line patients with hepatocellular carcinoma (HCC)
First European approval for the new Somatuline® delivery system

Attachment

YTD-2018-Sales-announcement

Ipsen delivers strong sales growth of 20.2% for the third quarter of 2018 and confirms full year guidance

Ipsen delivers strong sales growth of 20.2% for the third quarter of 2018 and confirms full year guidance

Ipsen delivers strong sales growth of 20.2% for the third quarter of 2018 and confirms full year guidance

Related Press Releases

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

Ipsen receives its second Shingo Prize for operational excellence

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases

Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance